Organic Process Research & Development 2005, 9, 827−829
Development of a Scalable Process for 1-â-Methyl Azetidinone: A Carbapenem
Key Intermediate†
Neera Tewari,* Hashim Nizar, Bishwa Prakash Rai, Avinash Mane, and Mohan Prasad
Chemical Research DiVision, Ranbaxy Research Laboratories, Gurgaon, Haryana - 122 001, India
Abstract:
An optimized process for the stereoselective synthesis of 1-â-
methyl carbapenem key intermediate (3S,4S)-[(R)-1′-((tert-
butyldimethylsilyl)oxy)ethyl]-4-[(R)-1-carboxyethyl]-2-azetidi-
none (1) and (3R,4R)-4-acetoxy-3-[(R)-1′-((tert-butyldimethyl-
silyl)oxy)ethyl]-2-azetidinone has been developed employing
commercially available chiral 4-phenyl-2-oxazolidinone. This
method provides an efficient and cost-effective process with
improved selectivity and higher yield.
tin enolate of 3-propionyl-2-thiazolidine thiones,7b,10 boron
enolate of 3-propionyl-2-thioazolidinone,7a or zirconium
enolate of thiol ester of propionic acid.11 These methods face
difficulties in large scale preparation of 1 as they employ
more than stoichiometric amounts of the precious chiral
sources and/or the expensive or toxic reagents. Different
oxazolidinthione derivatives have been used in the prepara-
tion of 1 resulting in low yield and varying â:R ratio.12 In
Introduction
The â-methyl carbapenem antibiotics exhibit excellent
broad spectrum antibacterial activities with increased chemi-
cal and metabolic stabilities as exemplified by Meropenem1,
addition the stereoselective synthesis of the key intermediate
1 via a Reformatsky type reaction employing different 3-(2-
Biapenem,2 and Ertapenem.3,4 (3S,4S)-[(R)-1′-((tert-Butyldim-
bromopropyl)-2-oxazolidinones using zinc has been re-
ethylsilyl)oxy)ethyl]-4-[(R)-1-carboxyethyl]-2-azetidinone (1)
is a key intermediate for the synthesis of â-methyl carbap-
enems. Many synthetic methods have been reported for the
ported.13 However, these oxazolidinone auxiliaries are dif-
ficult to access and expensive. Recently, a commercial
method has been reported for the preparation of 1 employing
synthesis of â-methyl azetidinone derivative 15 of which C-4
a Reformatsky type reaction using nonchiral dihydrooxazi-
alkylation of commercially available (3R,4R)-4-acetoxy-3-
[(R)-1′-((tert-butyldimethylsilyl)oxy)-ethyl]-2-azetidinone5 (2)
none derivatives.14 The best diastereoselectivity reported in
terms of the â:R ratio of the methyl group is 92:8. Another
with different types of enolates derived from propionic acid
diastereoselective synthesis is reported using a titanium
derivatives is the most important method for its commercial
enolate of 2′-hydroxy propiophenone6a which involves ozo-
preparations.6 Different metal enolates of propionic acid
nolysis at -78 °C and column chromatography. Herein we
derivatives having chiral and achiral auxiliary have been
report the process development work for the stereoselective
utilized, including 2-oxazolidinones,7 2-picolyl thiols,8 and
synthesis of (3S,4S)-[(R)-1′-((tert-butyldimethylsilyl)oxy)-
2,3-dihydro-4H-1,3-benzoxazin-4-one9 for improved â-se-
ethyl]-4-[(R)-1-carboxyethyl]-2-azetidinone (1) utilizing com-
lectivity in the preparation of 1. Stereoselective introduction
mercially available (S)-4-phenyl-2-oxazolidinone (3).
of the 1-â-methyl substituent in 2 has been achieved using
Results and Discussion
* Author for correspondence. E-mail: neera.tiwari@ranbaxy.com. Tele-
We explored the possibility of using commercially avail-
able chiral (S)-4-phenyl-2-oxazolidinone (3) as an auxiliary
for the synthesis of 1. The reaction of 3 with propionyl
phone: (91-124) 5011832. Fax: (91-124) 5011832.
† A patent application incorporating parts of this report has been filed.
(1) Sunagawa, M.; Matsamura, H.; Takaasi, I.; Fukasawa, M.; Kato, M. J.
Antibiot. 1990, 43, 519-532.
(2) Malonski, G. J.; Collins, I.; Wiennerstein, C.; Moellering, R. C.; Eliopoulos,
chloride in the presence of triethylamine results in the
G. M. Antimicrob. Agents Chemother. 1993, 37, 2009-2016.
formation of N-propionyl oxazolidinone derivative 4 (Scheme
(3) Sunagawa, M.; Sasaki, A. Heterocycles 2001, 54, 497-528.
1). This derivative is treated with titanium tetrachloride in
the presence of a tertiary amine base followed by reaction
with 2. After workup the condensed product 5 obtained is
(4) Cunha, B. A. Drugs Today 2002, 38, 195-213.
(5) Berks, A. H. Tetrahedron 1996, 52, 331-375.
(6) (a) Lee, Y. S.; Choung, W. K.; Kim, K. H.; Kang, T. W.; Ha, D. C.
Tetrahedron 2004, 60, 867-870. (b) Kondo, K.; Seki, M.; Kuroda, T.;
Yamanaka, T.; Iasaki, T. J. Org. Chem. 1995, 60, 1096-1097. (c) Ito, Y.;
Sasaki, A.; Tamato, K.; Sunagawa, M.; Terashima, S. Tetrahedron 1991,
47, 2801-2820.
(7) (a) Fuentes, L. M.; Shinkai, I.; Salzmann, T. N. J. Am. Chem. Soc. 1986,
108, 4675-4676. (b) Nagao, Y.; Kamagai, T.; Tamai, S.; Abe, T.;
Kuramoto, Y.; Taga, T.; Aoyagi, S.; Nagase, Y.; Ochaiai, M.; Inoue, Y.;
Fujita, E. J. Am. Chem. Soc. 1986, 108, 4673-4675.
(8) Martel, A.; Daris, J. P.; Bachand, C.; Corbeil, J.; Menard, M. Can. J. Chem.
1988, 66, 1537-1539.
(9) (a) Kondo, K.; Seki, M.; Kuroda, T.; Yamanaka, T.; Iwasaki, T. J. Org.
Chem. 1977, 62, 2877-2884.
(10) Deziel, R.; Favreau, D. Tetrahedron Lett. 1986, 27, 5687-5690.
(11) Kim, C. U.; Luh, B.; Partyka, R. A. Tetrahedron Lett. 1987, 28, 507-510.
(12) Nakagawa, Y.; Kiyohito, T.; Niigata, I. (Toyama) U.S. Patent 5,731,431,
1980.
(13) (a) Ito, Y.; Terashima, S. Tetrahedron Lett. 1987, 28, 6625-6628. (b)
Terashima, S.; Ito, Y.; Kawabata, T.; Sakai, K.; Hiyama, T.; Kimura, Y.;
Sunagawa, M.; Tomoto, K.; Sasaki, A. (Sumitomo) U.S. Patent 5,231,-
179, 1993.
(14) Lu, X.; Xu, Z.; Yang, G.; Fan, R. Org. Process Res. DeV. 2001, 5 (2),
186-188.
10.1021/op0501085 CCC: $30.25 © 2005 American Chemical Society
Published on Web 09/10/2005
Vol. 9, No. 6, 2005 / Organic Process Research & Development
•
827